A Phase 2 Study of Defactinib and Avutometinib, in Combination With Nivolumab for Patients With Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma

Bookmark
Investigational drug late phase More information Active drug More information Moderate burden on patient More information

Trial Details

Sponsor: Emory University (other)

Phase: 2

Start date: July 31, 2024

Planned enrollment: 50

Last updated in HealthScout: Nov 2024

chevron Show Summary from Sponsor

Investigational Drug AI Analysis

chevron Show for: Defactinib (PF-04554878, VS-6063)

chevron Show for: Avutometinib (RO-5126766, CKI-27, CH-5126766, R-7304, RG-7304, VS-6766)

More Resources

Trial ID: NCT06495125
Copy trial ID
More trial details at ClinicalTrials.gov More info

chevron Show News & AI Analysis

HealthScout AI Analysis

Goal: The goal of this phase II clinical trial is to evaluate the efficacy of the combination of defactinib, avutometinib, and nivolumab in increasing progression-free survival at six months for patients with LKB1-mutant non-small cell lung cancer who have become refractory to prior anti-PD1 treatment. Secondary objectives include assessing overall survival, response rate, and safety, with exploratory biomarker studies incorporated as well.

Patients: The trial targets patients with advanced non-small cell lung cancer, specifically those with LKB1 mutations whose cancer has not responded to previous anti-PD1 therapy. These patients may also have metastases. Cohort A exclusively includes patients with KRAS mutations, adding a special focus on genetically defined subgroups within the advanced lung adenocarcinoma population.

Design: This is an interventional, non-randomized, open-label, single-arm study, enrolling approximately 50 participants. Patients will receive combination therapy, and continued treatment will be contingent upon disease non-progression or manageable toxicity levels.

Treatments: Participants will be treated with oral defactinib, a focal adhesion kinase inhibitor known for modest activity in previous trials with a notable side effect profile, and avutometinib, a dual RAF/MEK inhibitor designed to target the RAS-RAF-MEK pathway without activating resistance mechanisms common in MEK inhibitor monotherapy. Nivolumab, a PD-1 blocking monoclonal antibody, will complement these by facilitating anti-tumor immune responses.

Outcomes: The primary outcome is progression-free survival at six months. Secondary outcomes include additional assessments of progression-free survival up to five years, overall survival from initiation to death, duration of response from initial to subsequent disease progression, and incidence of treatment-related adverse events measured up to 30 days post-trial. These outcomes provide a comprehensive view of both clinical efficacy and safety.

Burden on patient: The trial presents a moderate patient burden. Participants must adhere to a tight schedule of oral and intravenous treatments, along with frequent visits for imaging, biopsies, and blood samples, which might contribute to logistical challenges and physical stress. The invasive procedures, including biopsies, and regular blood tests for monitoring require travel to clinical sites and commitment to the trial protocol, increasing the overall burden compared to standard care measures.

Eligibility Criteria More information

chevron Show Criteria

Sites (3)

Sort by distance to:
Clear

Emory University Hospital Midtown

Atlanta, Georgia, 30308, United States

[email protected] / No phone

Status: Not yet recruiting

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States

[email protected] / 404-778-5378

Status: Recruiting

Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342, United States

[email protected] / No phone

Status: Recruiting

Please help us improve by giving us feedback or feature requests. Email [email protected]
Copy email address
Email copied to clipboard